Regeneron is growing sales and its pipeline at a breathtaking pace, but the Tarrytown, New York, biotech is also heavily dependent on a single drug at the moment. Meanwhile, Swiss behemoth Roche is diverse, and it has the most promising late-stage pipeline in big pharma.
http://ift.tt/1TMWtlv
No comments:
Post a Comment